American Journal of Kidney Diseases最新文献

{"title":"Is There a Role for Pentoxifylline in Diabetic Kidney Disease?","authors":"David J Leehey,Rajiv Agarwal","doi":"10.1053/j.ajkd.2025.09.030","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.09.030","url":null,"abstract":"For many years, the only specific pharmacologic intervention to decrease end-stage renal disease (ESRD) in diabetic kidney disease (DKD) was renin-angiotensin system (RAS) blockade. Recently, sodium-glucose co-transporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid antagonists (MRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists have been introduced. However, there remains a need for new therapies. The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) has been shown to have anti-proteinuric and anti-inflammatory effects, and small randomized clinical trials and meta-analyses indicate that PTX may have therapeutic benefits in DKD. A large multicenter randomized clinical trial to determine whether PTX decreases time to ESRD or death is being conducted.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"401 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147495190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paid Employment and Ability to Work Among People Receiving Dialysis: A Systematic Review of Qualitative Studies.","authors":"Ao Zhang,Adam Martin,Karine Manera,Chandana Guha,Martin Howell,Patrizia Natale,Nicole Scholes-Robertson,Dharshana Sabanayagam,Adeera Levin,Wolfgang Winkelmayer,Kevin F Erickson,Germaine Wong,Allison Jaure,Anita van Zwieten","doi":"10.1053/j.ajkd.2026.01.008","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.01.008","url":null,"abstract":"RATIONALE & OBJECTIVEPeople receiving dialysis have reduced workforce participation, which can affect mental well-being and exacerbate the financial burden of dialysis. This study aimed to describe the experiences and perspectives of people receiving dialysis on employment and their ability to work.STUDY DESIGNSystematic review and thematic synthesis of qualitative studies.SETTING & STUDY POPULATIONSAdults aged 16 years and over receiving dialysis.SEARCH STRATEGY & SOURCESMEDLINE, Embase and PsycINFO were searched to May 2025 for qualitative and mixed-methods studies that reported the perspectives of people receiving dialysis on employment or ability to work.DATA EXTRACTIONText from results and conclusions of studies.ANALYTICAL APPROACHThematic synthesis.RESULTS37 studies involving 1374 participants from 17 countries/regions were included. Six themes were identified: impinging on capacity to work (lacking physical endurance and energy, battling with cognitive symptoms, grueling treatment schedule), narrowed vocational opportunities and financial insecurity (unfulfilled dreams and worry about job prospects, struggling to stay afloat financially), discrimination and stigma (overlooked by potential employers, being pushed out of jobs or fired, delaying or avoiding disclosure of dialysis), conducive workplace environments (empathy and support from managers and colleagues, occupational adjustments), managing dialysis around work (choosing a suitable dialysis type to support work, careful time management and scheduling), and fostering esteem, enjoyment and social connection.LIMITATIONSOnly English-language articles were included.CONCLUSIONSAmong people receiving dialysis, the symptom and treatment burdens, lack of workplace accommodations, and discrimination all compromised sustained employment. Conversely, supportive workplaces that implemented tailored occupational adjustments enabled work participation, thereby boosting psychosocial well-being. Workplace advocacy and flexible work arrangements, symptom management, and aligning dialysis modality choices and timing with work demands may help to improve participation and work ability among people on dialysis.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"146 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147495191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicaid Expansion and Optimal Starts of Treatment for Incident Kidney Failure.","authors":"Nicholas S Roetker,James B Wetmore,Jiannong Liu,Haifeng Guo,David T Gilbertson,Kirsten L Johansen","doi":"10.1053/j.ajkd.2026.01.007","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.01.007","url":null,"abstract":"RATIONALE & OBJECTIVEBeginning in 2014, some states expanded Medicaid eligibility to include additional low-income adults under age 65. Examining whether the expansion led to improvements in optimal treatment at the start of kidney failure has been understudied and was the focus of this investigation.STUDY DESIGNObservational cohort study.SETTING & PARTICIPANTSPatients aged 26-64 years represented in the United States Renal Data System initiating treatment for kidney failure between 2008 and 2019.EXPOSUREResidence in states that did or did not expand Medicaid in 2014.OUTCOMEOptimal start of kidney failure treatment was defined as undergoing preemptive kidney transplantation, initiating home dialysis, or initiating in-center hemodialysis using an arteriovenous access.ANALYTICAL APPROACHInterrupted time series analyses were implemented to evaluate the adjusted association of residence in a Medicaid expansion state and optimal kidney failure treatment by comparing the trend in optimal kidney failure treatment starts during the pre-expansion vs. the post-expansion periods.RESULTSBefore Medicaid expansion, the percentage with optimal starts increased similarly in expansion and non-expansion states. After Medicaid expansion, the percentage with optimal starts continued increasing in expansion states but decreased in non-expansion states, resulting in a 3.9% (95% CI 0.5%, 7.2%) higher percentage with optimal starts in expansion vs. non-expansion states by 2019 (P=0.02 for post vs. pre change in trend). Most of the change in trend was attributable to a greater increase in use of home dialysis at initiation of kidney failure treatment in expansion vs. non-expansion states (difference 0.29% per year [95% CI 0.08%, 0.51%]) during the post-expansion period.LIMITATIONSPotential for unmeasured confounding from state-level factors other than Medicaid expansion.CONCLUSIONSMedicaid expansion was associated with an increasing percentage of patients with incident kidney failure experiencing an optimal start to treatment, driven mostly by an increase in the use of home dialysis. Expanding Medicaid coverage may offer an opportunity to improve treatment for low-income patients initiating kidney replacement therapy.PLAIN-LANGUAGE SUMMARYThis study examined whether the expansion of Medicaid eligibility in 2014 led to improvements in the percentage of patients receiving an optimal start (i.e., kidney transplantation before the need to start dialysis, initiation of home dialysis, or initiation of in-center hemodialysis using an arteriovenous access) to treatment for new-onset kidney failure. We compared trends from 2008 to 2019 across U.S. states that expanded Medicaid and those that did not. Before 2014, both groups showed a similar upward trend in optimal starts. However, after Medicaid expansion, states that expanded Medicaid continued to experience a rise in optimal starts while states that did not expand showed a decline over time. Much of the difference was explaine","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"57 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147495193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dialysis Facility Closures in the US From 2018 to 2024: A Serial Cross-Sectional Study.","authors":"Meri R J Varkila,Maria Montez-Rath,Xue Yu,Nivetha Subramanian,Douglas K Owens,Brian Brady,Geoffrey A Block,Julie Parsonnet,Glenn M Chertow,Shuchi Anand","doi":"10.1053/j.ajkd.2025.12.003","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.12.003","url":null,"abstract":"RATIONALE & OBJECTIVEBetween 2006-2016, the number of US dialysis facilities experienced steady annual growth. Recent data suggest a reversal in this trend. We examined trends in US dialysis facility closures and associated facility- and neighborhood-level characteristics.STUDY DESIGNSerial cross-sectional study of dialysis facilities from 2018 through 2024.SETTING & PARTICIPANTSDialysis facilities in the United States.EXPOSURESCalendar year; census region; census tract social vulnerability index; rural or urban area designation; racial and ethnic composition; coronavirus-19 mortality; dialysis facility payer mix, size, and profit status.OUTCOMESNumber of dialysis facility closures; temporal change in number of facilities by census tract.ANALYTICAL APPROACHDialysis facilities listed in the Provider of Services data from Centers for Medicare and Medicaid Services were used to determine openings and closures by quarter. Geocoded dialysis facility data were linked to the American Community Survey, rural urban commuting area codes, and the United States Renal Data System to describe associated facility- and neighborhood-level characteristics of closed facilities, and of census tracts without any remaining dialysis facilities.RESULTS8343 unique dialysis facilities were identified across 7222 census tracts from 2018 through 2024. Annual opening-to-closure ratios were 8.9 (2018: 401 openings, 45 closures), 2.7 (2019: 293 openings, 105 closures), 4.3 (2020: 218 openings, 51 closures), 1.5 (2021: 171 openings, 111 closures), 0.6 (2022: 123 openings, 210 closures), 0.5 (2023: 94 openings, 207 closures), and 0.8 (2024: 56 openings,74 closures). Closures exceeded openings between fourth quarter, 2021 and first quarter, 2024 (n=500, 62.2% of all closures during study period). Closed facilities were smaller than facilities that remained open (median size 58 [25th, 75th percentile 34, 96] for closed versus 112 [66, 165] for open facilities). Closures were observed more frequently in rural versus urban areas (11.2% versus 9.3%, respectively), and among facilities located in the Midwest versus the West (10.8% versus 7.7%, respectively). Closed facilities had a modestly higher proportion of patients eligible for both Medicaid and Medicare-dual eligibility, a marker of economic disadvantage-than facilities that remained open (mean proportion of census dual eligible 36.1% versus 34.6%).LIMITATIONSLack of data on patient outcomes.CONCLUSIONSNationwide, an increasing number of US dialysis facilities closed between 2018 and 2024, with smaller facilities, and rural and Midwest communities disproportionately affected. The patient-level implications of this trend require further study.PLAIN-LANGUAGE SUMMARYUntil recently, the number of dialysis facilities in the US was increasing, but this trend may have reversed in 2022. This study assessed whether dialysis facility closures were relatively more common in rural or socially vulnerable areas. It found a drastic increase in","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"236 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147495189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family Physicians’ Perspectives on Providing Living Kidney Donor Care","authors":"Chloe Wong-Mersereau , Saly El Wazze , Kathleen Gaudio , Katya Loban , Shaifali Sandal","doi":"10.1053/j.ajkd.2025.09.018","DOIUrl":"10.1053/j.ajkd.2025.09.018","url":null,"abstract":"<div><h3>Rationale & Objective</h3><div>Living kidney donors (LKDs) perceive gaps in care along their donation journeys, such as poor coordination and communication between providers. Better integration of their primary care providers (PCPs) in their donation journey can help address these gaps. We captured the perspectives of Canadian PCPs to understand the challenges they perceive when caring for LKDs and their recommendations to address them.</div></div><div><h3>Study Design</h3><div>Qualitative descriptive design.</div></div><div><h3>Setting & Participants</h3><div>Semistructured in-depth interviews with 19 family physicians conducted until data saturation.</div></div><div><h3>Analytical Approach</h3><div>Thematic analysis.</div></div><div><h3>Results</h3><div>Participants highlighted several challenges with the current living kidney donation processes: (1) limited scope of LKD care in primary practice; (2) poor clarity surrounding roles and responsibilities before donation (perceived as a facilitator) and after donation (perceived as low-barrier and high-access resource, and providing soft psychosocial support); (3) variable understanding of the living kidney donation process; and 4) lack of support and resources (patient accessibility to primary care, communication challenges between providers, poor health record transmission, limited availability of mental health services, limited financial support for patients and providers). The participants had 3 key recommendations: (1) support PCPs with pragmatic approaches and on-demand resources; (2) empower LKDs to be active participants in their care; and (3) implement strategies to address LKD care provision deficiencies (primary care accessibility, developing a collaborative care model, improving communication between all stakeholders, dedicated and prolonged psychosocial support, and governmental prioritization).</div></div><div><h3>Limitations</h3><div>About half the sample had limited experience with LKD care; inability to recruit some PCPs such as nurse practitioners.</div></div><div><h3>Conclusions</h3><div>As co-providers of patient care during the predonation phase and the primary drivers of care in the postdonation period, PCPs are positioned to deliver high-quality care to LKDs, contribute to long-term data collection, and potentially improve LKD outcomes. This study outlines challenges PCPs perceive and possible approaches to address them.</div></div><div><h3>Plain-Language Summary</h3><div>Living kidney donors (LKDs) have reported gaps in their care, such as poor communication and a lack of coordination between doctors. Because family physicians play a key role in supporting donors before and after surgery, we interviewed 19 Canadian family doctors to hear their perspectives. Participants reported challenges such as unclear roles, limited scope of seeing LKDs in their practices, poor communication with transplant centers, and a lack of mental health and financial services. The","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 376-387.e1"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Fatty Liver Disease and the Risk of Nephrolithiasis: Findings From Two Prospective Cohort Studies","authors":"Song Bai , Xin Yang , Qiuju Sheng , Qing Zhang , Li Liu , Shaomei Sun , Xing Wang , Ming Zhou , Qiyu Jia , Kun Song , Kaijun Niu , Yang Ding , Yang Xia","doi":"10.1053/j.ajkd.2025.09.012","DOIUrl":"10.1053/j.ajkd.2025.09.012","url":null,"abstract":"<div><h3>Rationale & Objective</h3><div>Evidence is limited regarding the associations of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction–associated fatty liver disease (MAFLD) with the development of nephrolithiasis. This study assessed the associations of NAFLD and MAFLD with the risk of incident nephrolithiasis using data from 2 cohort studies conducted in the People’s Republic of China and the United Kingdom.</div></div><div><h3>Study Design</h3><div>Prospective cohort study.</div></div><div><h3>Setting & Participants</h3><div>26,490 participants without nephrolithiasis at baseline in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study (TCLSIH) and 294,577 participants in the UK Biobank.</div></div><div><h3>Exposure</h3><div>Fatty liver diagnosed by abdominal ultrasonography in the TCLSIH and by the Hepatic Steatosis Index in the UK Biobank. NAFLD and MAFLD were defined according to standard clinical criteria in both cohorts.</div></div><div><h3>Outcome</h3><div>Nephrolithiasis was confirmed by ultrasonography in the TCLSIH and identified through ICD-10 and OPCS-4 in the UK Biobank.</div></div><div><h3>Analytical Approach</h3><div>Cox proportional hazards regression analysis was used to assess the relationship between exposures and incident nephrolithiasis.</div></div><div><h3>Results</h3><div>The TCLSIH and the UK Biobank recorded 806 and 2,743 new cases of nephrolithiasis during a median follow-up period of 4 and 12 years, respectively. Participants in both cohorts showed a significantly increased risk of nephrolithiasis in the setting of NAFLD (TCLSIH: HR, 1.69 [95% CI, 1.46-1.95]; UK Biobank: HR, 1.66 [95% CI, 1.53-1.79]) and MAFLD (TCLSIH: HR, 1.79 [95% CI, 1.55-2.08]; UK Biobank: HR, 1.54 [95% CI, 1.42-1.66]) after multivariable adjustments.</div></div><div><h3>Limitations</h3><div>Observational nature limits causal inferences; generalizability limited outside of the cohorts studied; limited diagnostic approaches to detect nephrolithiasis; unavailability of stone composition data.</div></div><div><h3>Conclusions</h3><div>Both NAFLD and MAFLD are associated with a higher risk of nephrolithiasis. The results suggest that NAFLD/MAFLD and their associated metabolic conditions may represent modifiable risk factors for nephrolithiasis.</div></div><div><h3>Plain-Language Summary</h3><div>Evidence on the association between nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction–associated fatty liver disease (MAFLD) and the risk of nephrolithiasis remains limited. In this study, we assessed whether NAFLD or MAFLD were associated with an increased risk of developing nephrolithiasis by analyzing data from 2 large prospective cohorts in the People’s Republic of China and the United Kingdom. Our findings demonstrated that individuals with NAFLD or MAFLD had a significantly higher risk of incident nephrolithiasis later in life. This increased risk remained consistent across different age ","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 364-375.e1"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial Prophylaxis in US Medicare Beneficiaries Receiving Immunosuppressants for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis","authors":"Carolyn T. Thorpe , Ryan P. Hickson , Xinhua Zhao , Sherrie L. Aspinall , Vimal K. Derebail , Binxin Cao , Alexa Ehlert , Joshua M. Thorpe , Ronald J. Falk , Susan L. Hogan","doi":"10.1053/j.ajkd.2025.08.019","DOIUrl":"10.1053/j.ajkd.2025.08.019","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 393-396"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145746719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review","authors":"Jia Wei Teh ,&nbsp;Sinead Stoneman ,&nbsp;Michelle M. O’Shaughnessy","doi":"10.1053/j.ajkd.2025.07.023","DOIUrl":"10.1053/j.ajkd.2025.07.023","url":null,"abstract":"<div><div>IgA nephropathy (IgAN) is the most common immune-mediated glomerular disease worldwide. Advanced understanding of the role of complement in IgAN pathogenesis has motivated the development of complement inhibition as a therapeutic strategy. Iptacopan, a complement factor B inhibitor, is the first approved complement inhibitor for IgAN. Several other complement inhibitors are being studied in phase 2/3 clinical trials. How best to integrate complement inhibition into the evolving treatment paradigm for IgAN remains a challenge. This review provides an overview of the role of complement in the pathogenesis and progression of IgAN and summarizes current and emerging complement-targeted IgAN therapies.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 412-421"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Vaccination in People With CKD: Report From a National Kidney Foundation Working Group","authors":"Susan F. Massengill ,&nbsp;Kenneth A. Andreoni ,&nbsp;Keith A. Bellovich ,&nbsp;Cheryl Courtlandt ,&nbsp;Vimal K. Derebail ,&nbsp;David L. Feldman ,&nbsp;Gia J. Oh ,&nbsp;John W. Sleasman ,&nbsp;Kristina A. Bryant","doi":"10.1053/j.ajkd.2025.10.014","DOIUrl":"10.1053/j.ajkd.2025.10.014","url":null,"abstract":"<div><div>People with chronic kidney disease (CKD) are particularly vulnerable to vaccine-preventable infections. Therefore, the National Kidney Foundation organized a multidisciplinary working group, including people with CKD and family care partners, to develop recommendations to improve vaccination rates, vaccination effectiveness, and health care for the CKD population. A modified Delphi process was used to achieve consensus on the recommendations. Recommendations on vaccination in CKD patients were organized into these categories: (1) patient preferences; (2) assessing the vaccination status of patients with CKD; (3) assessing vaccine response in patients with CKD; (4) vaccination of immunocompromised patients; (5) vaccination in posttransplant patients; (6) vaccinations in patients with CKD before international travel; (7) vaccination of household contacts of patients with CKD; (8) assessing vaccine efficacy and safety in clinical trials with patients with CKD; (9) training and resources for health care teams; (10) training of health care teams for discussions with patients; (11) role of technology in promoting and improving vaccination; and (12) advocacy and policy considerations for promoting and improving vaccination rates. The working group’s recommendations should improve communication between patients and health care clinicians, inclusion of people with CKD in vaccine trials, and use of existing clinical guidelines as well as generate educational resources and training materials for CKD patients of all ages and health care professionals.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 402-411"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145823890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation Decisions in Patients With Kidney Failure Requiring Hemodialysis: Caught Between a Clot and a Hard Place","authors":"An S. De Vriese","doi":"10.1053/j.ajkd.2026.01.004","DOIUrl":"10.1053/j.ajkd.2026.01.004","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 292-294"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}